Dipeptidyl-peptidase 4 (DPP4)/CD26 inhibitors (gliptins), a class of hypoglycemic drugs, are currently registered in many countries for the treatment of type 2 diabetes [124]. Here, DPP4 is linked to type 2 diabetes mellitus.